SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:777deb21-b323-4a82-a732-d2eb9702f9de"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:777deb21-b323-4a82-a732-d2eb9702f9de" > International Asses...

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma

Maurer, Matthew J., (författare)
Mayo Clinic Minnesota
Ellin, Fredrik, (författare)
Forskargrupper vid Lunds universitet, Lund University Research Groups, Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Sektion V, Division V, Onkologi och Patologi, Kampradlab, Oncology and Pathology, Kamprad Lab, Lymfom - Klinisk forskning, Lymphoma - Clinical Research
Srour, Line (författare)
visa fler...
Jerkeman, Mats, (författare)
Forskargrupper vid Lunds universitet, Lund University Research Groups, Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Sektion V, Division V, Onkologi och Patologi, Kampradlab, Oncology and Pathology, Kamprad Lab, Lymfom - Klinisk forskning, Lymphoma - Clinical Research, Strategiska forskningsområden, Strategic Research Areas, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, Starka forskningsmiljöer, Strong Research Environments
Bennani, N. Nora, (författare)
Mayo Clinic Minnesota
Connors, Joseph M. (författare)
Slack, Graham W. (författare)
Smedby, Karin E. (författare)
Ansell, Stephen M., (författare)
Mayo Clinic Minnesota
Link, Brian K. (författare)
Cerhan, James R. (författare)
Relander, Thomas, (författare)
Forskargrupper vid Lunds universitet, Lund University Research Groups, Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Sektion V, Division V, Onkologi och Patologi, Kampradlab, Oncology and Pathology, Kamprad Lab, Lymfom - Klinisk forskning, Lymphoma - Clinical Research
Savage, Kerry J. (författare)
Feldman, Andrew L., (författare)
Mayo Clinic Minnesota
visa färre...
Lunds universitet Onkologi och Patologi, Kampradlab. (creator_code:org_t)
Lunds universitet Lymfom - Klinisk forskning. (creator_code:org_t)
visa fler...
Lunds universitet BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation. (creator_code:org_t)
visa färre...
2017
Engelska 8 s.
Ingår i: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - American Society of Clinical Oncology. - 1527-7755. ; 35:36, s. 4019-4026
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavior. We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma. Here, we assess EFS24 and subsequent overall survival (OS) in large, multinational PTCL cohorts. Patients and Methods Patients with systemic PTCL newly diagnosed from 2000 to 2012 and treated with curative intent were included from the United States and Sweden (initial cohorts) and from Canada (replication cohort). EFS was defined as time from date of diagnosis to progression after primary treatment, retreatment, or death. Subsequent OS was measured after achieving EFS24 or from the time of progression if it occurred within 24 months. OS rates were compared with the age-, sex-, and country-matched general population. Results Seven hundred seventy-five patients were included in the study (the median age at diagnosis was 64 years; 63% were men). Results were similar in the initial and replication cohorts, and a combined analysis was undertaken. Sixty-four percent of patients progressed within the first 24 months and had a median OS of only 4.9 months (5-year OS, 11%). In contrast, median OS after achieving EFS24 was not reached (5-year OS, 78%), although relapses within 5 years of achieving EFS24 occurred in 23% of patients. Superior outcomes after achieving EFS24 were observed in younger patients (≤ 60 years of age: 5-year OS, 91%). Conclusion EFS24 stratifies subsequent outcome in PTCL. Patients with PTCL with primary refractory disease or early relapse have extremely poor survival. However, more than one third of patients with PTCL remain in remission 2 years after diagnosis with encouraging subsequent OS, especially in younger patients. These marked differences in outcome suggest that EFS24 has utility for patient counseling, study design, and risk stratification in PTCL.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy